Grant: Operating Grant
McGill University
$319,335.00
Resistance of Citrobacter rodentium and related enteric pathogens to antimicrobial peptides
EF 2009-10
Résumé
Antimicrobial peptides are an important component of the human innate immune system against bacteria and other pathogens. It is now known that the invasive pathogen Salmonella enterica is able to defeat the action of antimicrobial peptides by recognizing these peptides and mounting a counter attack. In Salmonella enterica, the PhoPQ two-component system senses host antimicrobial peptides and triggers an adaptive response that consists of decreasing the permeability of the bacterial cell surface to antimicrobial peptides. PhoPQ is also present in non-invasive enteric pathogens like enteropathogenic Escherichia coli (EPEC) and enterohemorrhagic E. coli (EHEC, e.g. E. coli O157:H7). Using the murine pathogen Citrobacter rodentium, which causes the same type of disease than EPEC and EHEC, we propose a research plan to determine whether these clinically relevant bacterial pathogens use similar molecular mechanisms to defeat the action of antimicrobial peptides produced by mucosal tissues. By testing in mice Citrobacter rodentium mutants in which, for example, the phoPQ genes have been disrupted, we will be able to determine whether these genes are essential for bacterial pathogenicity. A better understanding of these mechanisms that are at the host-pathogen interface will allow the development of novel therapeutic strategies. For example, drugs directed against PhoPQ are likely to enhance the bactericidal effect of the naturally produced antimicrobial peptides. These new antimicrobials that target bacterial pathogenicity rather than bacterial growth are less likely to favor the emergence of drug-resistant pathogens.
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
189520
Name
Le Moual Hervé
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Microbiology & Infectious Diseases
Projecttitle
Resistance of Citrobacter rodentium and related enteric pathogens to antimicrobial peptides
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$319,335
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Antimicrobial Peptides; Bacterial Virulence; Host-Pathogen Interactions; Lipopolysaccharide; Outer Membrane; Two-Component Systems
Abstract
Antimicrobial peptides are an important component of the human innate immune system against bacteria and other pathogens. It is now known that the invasive pathogen Salmonella enterica is able to defeat the action of antimicrobial peptides by recognizing these peptides and mounting a counter attack. In Salmonella enterica, the PhoPQ two-component system senses host antimicrobial peptides and triggers an adaptive response that consists of decreasing the permeability of the bacterial cell surface to antimicrobial peptides. PhoPQ is also present in non-invasive enteric pathogens like enteropathogenic Escherichia coli (EPEC) and enterohemorrhagic E. coli (EHEC, e.g. E. coli O157:H7). Using the murine pathogen Citrobacter rodentium, which causes the same type of disease than EPEC and EHEC, we propose a research plan to determine whether these clinically relevant bacterial pathogens use similar molecular mechanisms to defeat the action of antimicrobial peptides produced by mucosal tissues. By testing in mice Citrobacter rodentium mutants in which, for example, the phoPQ genes have been disrupted, we will be able to determine whether these genes are essential for bacterial pathogenicity. A better understanding of these mechanisms that are at the host-pathogen interface will allow the development of novel therapeutic strategies. For example, drugs directed against PhoPQ are likely to enhance the bactericidal effect of the naturally produced antimicrobial peptides. These new antimicrobials that target bacterial pathogenicity rather than bacterial growth are less likely to favor the emergence of drug-resistant pathogens.
Competitiondate
200909
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Le Moual, Hervé
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $319,335~ $0~